Sen. John Boozman Sells Off Shares of Boston Scientific Corporation (NYSE:BSX)

Senator John Boozman (R-Arkansas) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on January 13th, the Senator disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on December 17th.

Senator John Boozman also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of iShares S&P 500 Growth ETF (NYSEARCA:IVW) on 12/31/2025.
• Sold $1,001 – $15,000 in shares of Super Micro Computer (NASDAQ:SMCI) on 12/31/2025.
• Sold $1,001 – $15,000 in shares of SPDR S&P Regional Banking ETF (NYSEARCA:KRE) on 12/26/2025.
• Purchased $1,001 – $15,000 in shares of iShares Core S&P Small-Cap ETF (NYSEARCA:IJR) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of iShares Silver Trust (NYSEARCA:SLV) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of abrdn Physical Platinum Shares ETF (NYSEARCA:PPLT) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of abrdn Physical Palladium Shares ETF (NYSEARCA:PALL) on 12/24/2025.
• Purchased $15,001 – $50,000 in shares of Tradr 2X Long SPY Monthly ETF (NASDAQ:SPYM) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Motorola Solutions (NYSE:MSI) on 12/17/2025.
• Purchased $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 12/17/2025.

Boston Scientific Trading Down 0.5%

Shares of NYSE:BSX traded down $0.45 during trading on Wednesday, reaching $93.69. The stock had a trading volume of 7,270,235 shares, compared to its average volume of 8,337,404. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The firm’s fifty day moving average is $97.43 and its 200 day moving average is $100.58. The stock has a market cap of $138.89 billion, a price-to-earnings ratio of 50.10, a P/E/G ratio of 1.69 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business’s revenue was up 20.3% compared to the same quarter last year. During the same period last year, the business posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Farapoint pulsed-field ablation (PFA) catheter strengthens Boston Scientific’s electrophysiology (EP) franchise and supports near-term revenue upside as the company scales PFA adoption. Boston Scientific wins FDA nod for Farapoint PFA catheter
• Positive Sentiment: CE mark awarded for the Embold detachable coil system expands the company’s neurovascular product footprint in Europe, adding another high-margin device to drive procedure share. Boston Scientific wins CE mark for Embold detachable coil system
• Positive Sentiment: Agreement to acquire Valencia Technologies strengthens Boston Scientific’s urology/pelvic health pipeline and supports the company’s strategic push into higher-growth pelvic-health devices. Analysts see the deal as accelerating revenue diversification in a high-growth segment. Boston Scientific to buy incontinence device maker Valencia
• Positive Sentiment: Planned expansion in Maple Grove adds manufacturing capacity to support growth in urology and implantable devices, a signal of management’s confidence in demand and a long-term positive for supply-side scaling. Boston Scientific plans expansion in Maple Grove
• Positive Sentiment: Multiple Wall Street analysts have reiterated Buy ratings and positive commentary after recent approvals and M&A — highlighting diversified growth engines (EP, neuro, urology/pelvic health) and execution as reasons for upside to consensus. Boston Scientific: Farapoint PFA Approval Strengthens EP Ecosystem and Supports Buy Rating
• Neutral Sentiment: Company presentation/transcript from the J.P. Morgan Healthcare Conference provides additional management commentary and longer-term sales/guidance context for investors but contains no new disruptive surprises. Boston Scientific Corporation (BSX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Negative Sentiment: Market commentary notes the stock has pulled back despite positive newsflow; investors may be digesting recent gains (valuation concerns — BSX carries a premium P/E) and technical resistance around moving averages, which can pressure the share price in the short term. Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note

Institutional Investors Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Waycross Partners LLC purchased a new stake in shares of Boston Scientific in the fourth quarter worth $2,384,000. Southland Equity Partners LLC grew its position in Boston Scientific by 13.7% during the 4th quarter. Southland Equity Partners LLC now owns 2,664 shares of the medical equipment provider’s stock valued at $254,000 after purchasing an additional 320 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in Boston Scientific by 1.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 65,288 shares of the medical equipment provider’s stock valued at $6,225,000 after purchasing an additional 625 shares in the last quarter. Wealthcare Advisory Partners LLC raised its holdings in Boston Scientific by 6.7% in the fourth quarter. Wealthcare Advisory Partners LLC now owns 3,849 shares of the medical equipment provider’s stock worth $367,000 after buying an additional 243 shares during the last quarter. Finally, Avity Investment Management Inc. grew its holdings in shares of Boston Scientific by 34.0% during the fourth quarter. Avity Investment Management Inc. now owns 217,749 shares of the medical equipment provider’s stock valued at $20,762,000 after buying an additional 55,223 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on BSX. The Goldman Sachs Group reiterated a “buy” rating and issued a $112.00 price target on shares of Boston Scientific in a report on Friday, January 9th. Citigroup reaffirmed a “buy” rating on shares of Boston Scientific in a report on Wednesday. Barclays boosted their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Finally, Cowen reissued a “buy” rating on shares of Boston Scientific in a report on Thursday, December 11th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $125.21.

Insider Activity

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 93,095 shares of company stock valued at $9,305,450 in the last quarter. 0.50% of the stock is currently owned by insiders.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.